Trials / Unknown
UnknownNCT02934048
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies. However, due to the increasing resistance rates to antibiotics, failures of H. pylori eradication get more and more common. Thus, rescue therapy for persistent H. pylori infection is becoming a grand challenge the investigators have to face.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 7-day triple regimen guided by AST | Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated. |
| OTHER | 10-day triple regimen guided by AST | Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated. |
| OTHER | 14-day triple regimen guided by AST | Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2016-10-14
- Last updated
- 2016-10-14
Source: ClinicalTrials.gov record NCT02934048. Inclusion in this directory is not an endorsement.